A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Excluded: EGFR activating mutation

prior targeted therapy, including but not limited to those targeting EGFR activating mutations

Excluded: ALK fusion

prior targeted therapy, including but not limited to those targeting ... ALK fusions

Excluded: ROS1 rearrangement

prior targeted therapy, including but not limited to those targeting ... ROS rearrangements

Excluded: RET fusion

prior targeted therapy, including but not limited to those targeting ... RET fusions or mutations

Excluded: RET mutation

prior targeted therapy, including but not limited to those targeting ... RET fusions or mutations

Excluded: BRAF v600e

prior targeted therapy, including but not limited to those targeting ... BRAF V600E mutation

Excluded: MET exon 14 skipping mutation

prior targeted therapy, including but not limited to those targeting ... MET exon 14 skipping mutation

Excluded: KRAS g12c

prior targeted therapy, including but not limited to those targeting ... KRAS G12C mutation

Cannot have received: HMBD-001 (HMBD-001)

Prior treatment with HMBD-001

Cannot have received: cetuximab (cetuximab)

Prior treatment with cetuximab

Cannot have received: docetaxel (docetaxel)

Exception: Prior treatment with docetaxel is allowed for Arm C

Prior treatment with docetaxel is allowed for Arm C

Cannot have received: EGFR-targeted therapy

Prior treatment with any other agent that targets Epidermal Growth Factor Receptor (EGFR)

Cannot have received: HER3-targeted therapy

Prior treatment with any other agent that targets HER3

Cannot have received: pan-HER inhibitor

Prior treatment with pan-HER inhibitors